Skip to content

US · IMCR · BIOTECHNOLOGY

Immunocore Holdings plc (IMCR) intrinsic value and stock valuation

$26.41as of 2026-11-21 · Mkt cap 1.73B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immunocore Holdings plc DCF and intrinsic value

InvestorsCraft values IMCR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IMCR’s statements →

Immunocore Holdings plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Abingdon, OX OX14 4RY immunocore.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$297.6M+58.1% 5y CAGRd
20132025
Net income
-$-26.42M
20132025
Free cash flow
-$-11.2M
20132025
Total equity
$381M+47.1% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$297.6M$248M$197.4M$144.2M$27M
Operating income-$-33.74M-$-56.28M-$-47.2M-$-42.77M-$-129.42M
Net income-$-26.42M-$-40.81M-$-43.75M-$-43.46M-$-133.45M
EPSd-$-524.73K-$-816.36K-$-894.87K-$-950.78K-$-3.04M
Operating cash flow-$-7.97M$26.1M$2.33M-$-49.21M-$-143.11M
Capital expenditure-$-3.23M-$-5.17M-$-4.29M-$-2.2M-$-1.39M
Free cash flow-$-11.2M$20.9M-$-1.97M-$-51.41M-$-144.49M
Total assets$1.07B$1.01B$472.4M$526.8M$407.3M
Total debt$436.7M$432.7M$66.5M$81.5M$86.2M
Net debt-$-31.02M-$-23.01M-$-283.77M-$-321.02M-$-234.9M
Total equity$381M$360.7M$291.9M$338.9M$231.5M
Cash and short-term investments$864.2M$820.4M$350.3M$402.5M$321.1M
Income statement
20252024202320222021
Revenue$297.6M$248M$197.4M$144.2M$27M
Cost of revenue$6.21M$5.54M$820K$5.29M$0.00
Gross profit$291.4M$242.4M$196.6M$138.9M$27M
Research and development expenses$204.5M$177.4M$129.4M$84.3M$74.3M
Selling, general and administrative expenses$120.6M$121.2M$114.4M$0.00$82.2M
Other expenses$0.00$150K$0.00$97.4M$0.00
Operating expenses$325.1M$298.8M$243.8M$181.7M$156.5M
Cost and expenses$331.3M$304.3M$244.6M$187M$156.5M
Interest income$16.5M$25.6M$14.2M$3.76M$70K
Interest expense$12.2M$18.8M$4.08M$5.41M$5.57M
Depreciation and amortization$2.43M$3.36M$3.24M$4.41M$5.63M
Ebitda$390K-$-38.5M-$-40.87M-$-38.35M-$-123.58M
Operating income-$-33.74M-$-56.28M-$-47.2M-$-42.77M-$-129.42M
Total other income/expenses, net$19.5M$14M-$-980K$8.95M-$-3.92M
Income before tax-$-14.21M-$-42.32M-$-48.19M-$-33.82M-$-133.34M
Income tax expense$12.2M-$-1.48M-$-4.43M$9.65M$110K
Net income-$-26.42M-$-40.81M-$-43.75M-$-43.46M-$-133.45M
Weighted average shares outstanding$50.4M$50M$48.9M$45.7M$42.5M
Weighted average diluted shares outstanding$50.4M$50M$48.9M$45.7M$43.9M
Balance sheet
20252024202320222021
Cash and short-term investments$864.2M$820.4M$350.3M$402.5M$321.1M
Net receivables$74M$83.1M$48.6M$57.1M$33.5M
Inventory$6.74M$5.45M$3.56M$690K$0.00
Total current assets$996.7M$929.9M$418.5M$474M$354.6M
Property, plant and equipment, net$50.2M$47.7M$33.8M$38.8M$42.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$140K$220K
Total non-current assets$70.5M$79.6M$54M$52.8M$52.7M
Total assets$1.07B$1.01B$472.4M$526.8M$407.3M
Accounts payable$24.4M$25.1M$14.1M$14.5M$10.1M
Short-term debt$2.01M$1.55M$1.1M$1.88M$1.69M
Deferred revenue$580K$0.00$0.00$7.76M$33M
Total current liabilities$246.7M$212.2M$110M$100.8M$82.6M
Long-term debt$434.7M$431.2M$65.4M$79.6M$84.5M
Deferred revenue, non-current$4.86M$5.43M$4.36M$5.24M$8.65M
Total non-current liabilities$439.5M$436.6M$70.5M$87M$93.2M
Capital lease obligations$43.6M$41.7M$28.5M$33.6M$35.9M
Total liabilities$686.2M$648.8M$180.6M$187.9M$175.8M
Common stock$140K$140K$80K$130K$120K
Retained earnings-$-831.27M-$-795.76M-$-589.3M-$-689.39M-$-649.7M
Accumulated other comprehensive income (loss)-$-28.08M-$-33.76M-$-28.7M-$-54.67M$521.3M
Total equity$381M$360.7M$291.9M$338.9M$231.5M
Total investments$396.4M$364.6M$0.00$140K$220K
Total debt$436.7M$432.7M$66.5M$81.5M$86.2M
Net debt-$-31.02M-$-23.01M-$-283.77M-$-321.02M-$-234.9M
Cash flow statement
20252024202320222021
Net income-$-26.42M-$-51.09M-$-34.32M-$-52.54M-$-180.03M
Depreciation and amortization$2.43M$4.2M$3.24M$5.33M$7.59M
Stock-based compensation$0.00$34.2M$25.7M$32.9M$48.9M
Change in working capital-$-6.92M$45.1M$4.58M-$-24.16M-$-21.96M
Accounts receivable-$-5.46M-$-12.35M-$-14.14M-$-26.26M-$-4.86M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.83M$7.27M$2.08M$4.91M$1.47M
Net cash provided by operating activities-$-7.97M$26.1M$2.33M-$-49.21M-$-143.11M
Investments in property, plant and equipment-$-3.23M-$-5.17M-$-3.37M-$-2.2M-$-1.39M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-12.16M-$-355.13M-$-4.29M-$-2.2M-$-1.28M
Common stock issued$9.2M$6.8M$0.00$139.5M$286.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.2M$343.9M$27.2M$145.4M$288.2M
Net change in cash$8.89M$13.1M$31.8M$81.4M$144.4M
Cash at end of period$347.1M$455.7M$350.3M$402.5M$321.1M
Operating cash flow-$-7.97M$26.1M$2.33M-$-49.21M-$-143.11M
Capital expenditure-$-3.23M-$-5.17M-$-4.29M-$-2.2M-$-1.39M
Free cash flow-$-11.2M$20.9M-$-1.97M-$-51.41M-$-144.49M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immunocore Holdings plc

        Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.

        CEO
        Bahija Jallal
        Employees
        524
        Beta
        0.73

        Explore

        Frequently asked questions

        What is the intrinsic value of Immunocore Holdings plc (IMCR)?

        Immunocore Holdings plc (IMCR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IMCR undervalued?

        IMCR trades at a price of $26.41 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.